Patent Grant
9561277
The present invention relates to an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof. More particularly, the present invention relates to an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester.
Benzoylphenylacetic acid derivatives including bromfenac (generic name) of formula (I):
of which chemical name is 2-amino-3-(4-bromobenzoyl)phenylacetic acid are known as disclosed in JP-A-23052/1977 and its corresponding U.S. Pat. No. 4,045,576. 2-Amino-3-(4-bromobenzoyl)phenylacetic acid, its pharmacologically acceptable salt and a hydrate thereof are known as a non-steroidal anti-inflammatory agent, and they are effective against inflammatory diseases of anterior or posterior segment of the eye, such as blepharitis, conjunctivitis, scleritis, and postoperative inflammation in the field of ophthalmology, and its sodium salt has been practically used in the form of eye drops (“New Drugs in Japan, 2001”, 2001 Edition, Published by Yakuji Nippo Ltd., May 11, 2001, p.27-29).
The eye drop as mentioned above is designed to stabilize 2-amino-3-(4-bromobenzoyl)phenylacetic acid by means of addition of a water-soluble polymer (e.g. polyvinylpyrrolidone, polyvinyl alcohol, etc.) and a sulfite (e.g. sodium sulfite, potassium sulfite, etc.) (Japanese patent No. 2,683,676 and its corresponding U.S. Pat. No. 4,910,225).
In addition, as an eye drop other than the above-mentioned one, Japanese patent No. 2,954,356 (corresponding to U.S. Pat. Nos. 5,603,929 and 5,653,972) discloses a stable ophthalmic composition which comprises incorporating an antibacterial quaternary ammonium polymer and boric acid into an acidic ophthalmic agent. The acidic agent described therein includes, for example, 2-amino-3-(4-bromobenzoyl)phenylacetic acid.
Further, in Japanese patent No. 2,954,356, there is the following description—“Benzalkonium chloride is a widely used preservative in ophthalmic solutions. However, benzalkonium chloride and other quaternary ammonium compounds are generally considered to be incompatible with ophthalmic compositions of drugs with acidic groups, such as nonsteroidal anti-inflammatory drugs. These preservatives lose their ability to function as they form complexes with the charged drug compounds”.
In these prior art references, there is no disclosure that alkyl aryl polyether alcohol type polymers or polyethylene glycol fatty acid esters are able to stabilize an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt, and inhibit decrease in preservative effect of benzalkonium chloride and other quaternary ammonium compounds.
It is an object of the present invention to provide an aqueous liquid preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which is stable within a pH range giving no irritation to eyes and in which, when a preservative such as benzalkonium chloride is incorporated therein, preservative effect of the preservative does not substantially deteriorate.
Another object of the invention is to provide a method for stabilizing an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof.
Further object of the invention is to provide an aqueous liquid preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a preservative wherein, when specifically a quaternary ammonium salt such as benzalkonium chloride is incorporated as a preservative, decrease in preservative effect of said preservative is inhibited.
As a result of various studies, the inventors of the present invention have found that, by adding, for example, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate to an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, the aqueous solution becomes stable within a pH range giving no irritation to eyes, and change of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid over time can be inhibited, and furthermore, when the aqueous solution contains a preservative, deterioration in the preservative effect of said preservative can be inhibited for a long period of time. The inventors of the present invention have further studied extensively and completed the present invention.
Namely, the present invention relates to:
According to the present invention, a stable aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof can be prepared by incorporating an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof. Also, an aqueous liquid preparation of the present invention, wherein a preservative is incorporated, has a sufficient preservative effect.
Therefore, the aqueous liquid preparation of the present invention is advantageously used as an eye drop for the treatment of, for example, blepharitis, conjunctivitis, scleritis, and postoperative inflammation. In addition, such aqueous liquid preparation can be used as a nasal drop for the treatment of, for example, allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
The pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid includes, for example, an alkali metal salt such as sodium salt and potassium salt, and an alkaline earth metal salt such as calcium salt and magnesium salt, among which sodium salt is especially preferable.
2-Amino-3-(4-bromobenzoyl)phenylacetic acid and its pharmacologically acceptable salt can be prepared according to the method as described in JP-A-23052/1977 (corresponding to U.S. Pat. No. 4,045,576) or by a similar method thereof. These compounds can be obtained as their hydrate depending on synthetic conditions and recrystallization conditions. The hydrate includes 1/2 hydrate, 1 hydrate, and 3/2 hydrate, among which 3/2 hydrate is preferable.
In the aqueous liquid preparation of the present invention, the content (concentration range) of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is usually about 0.01 to 0.5 w/v %, preferably about 0.05 to 0.2 w/v %, especially about 0.1 w/v %, and it is preferable to appropriately vary the content depending on the purpose of use and the degree of disease to be treated.
The carbon number of the alkyl in the an alkyl aryl polyether alcohol type polymer which is a non-ionic surfactant used as a stabilizer for 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is approximately 1 to 18. Specifically, the alkyl group includes, for example, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethylpropyl, 4-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 1,2-dimethylbutyl, 2-ethylbutyl, cyclopentyl, hexyl, cyclohexyl, heptyl, isoheptyl, octyl, isooctyl, nonyl, isononyl, decyl, isodecyl, undecyl, isoundecyl, dodecyl, isododecyl, tridecyl, isotridecyl, tetradecyl, isotetradecyl, pentadecyl, isopentadecyl, hexadecyl, isohexadecyl, heptadecyl, isoheptadecyl, octadecyl, isooctadecyl, and isomers thereof, among which octyl and its isomer (e.g. isooctyl, sec-octyl, 1-methylheptyl, 1-ethylhexyl, 2-ethylhexyl, 1-propylpentyl, 1,5-dimethylhexyl, 1,1,3,3-tetramethylbutyl, etc.) are preferable, and 1,1,3,3-tetramethylbutyl which is an isomer of octyl groups is especially preferable.
The aryl in the alkyl aryl polyether alcohol type polymer can be preferably a phenyl residue. The polyether alcohol can be represented by the formula O(CH2CH2O)xH in which X is an integer of 5 to 100, preferably 5 to 30, more preferably 8 to 10. The average polymerization degree is preferably about 3 to 10.
Among the above-mentioned alkyl aryl polyether alcohol type polymers, tyloxapol having the following formula is especially preferable.
The fatty acid of the polyethylene glycol fatty acid ester which is a non-ionic surfactant used as a stabilizer for 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof can be preferably a fatty acid having the carbon number of 12 to 18. Specific examples of such polyethylene glycol fatty acid esters are polyethylene glycol monostearate (e.g. polyoxyl 8 stearate, polyoxyl 40 stearate, etc.), polyethylene glycol monolaurate, polyethylene glycol monooleate, polyethylene glycol diisostearate, polyethylene glycol dilaurate, polyethylene glycol dioleate, and the like. Among these compounds, polyethylene glycol monostearate is preferable, and polyoxyl 40 stearate is especially preferable. The polyoxyl 40 stearate is a monostearic acid ester of an ethylene oxide condensed polymer, and can be represented by the formula C17H35COO(CH2CH2O)nH which is a non-ionic surfactant and n is about 40.
Although the content (concentration range) of the alkyl aryl polyether alcohol type polymer in the aqueous liquid preparation of the present invention depends on the kind of compounds used, the minimum concentration is about 0.01 w/v % and the maximum concentration is about 0.5 w/v %. With respect to the tyloxapol content (concentration range), for example, the minimum content is about 0.01 w/v %, 0.02 w/v or 0.03 w/v %, and the maximum content is about 0.05 w/v %, 0.1 w/v %, 0.3 w/v % or 0.5% w/v, and preferably the minimum content is about 0.02 w/v % and the maximum content is about 0.05 w/v %.
Although the content (concentration range) of the polyethylene glycol fatty acid ester in the aqueous liquid preparation of the present invention depends on the kind of compounds used, it is within a range of about 0.02 w/v % of minimum concentration to about 0.1 w/v % of maximum concentration. For example, the content (concentration range) of polyethylene glycol monostearate is within a range of about 0.02 w/v of minimum content to about 0.1 w/v of maximum content, and preferably within a range of about 0.02 w/v % of the minimum content to about 0.05 w/v of the maximum content.
The incorporation ratio of tyloxapol in the aqueous liquid preparation of the invention is within a range of the minimum content of about 0.1 or 0.2 part by weight to the maximum content of about 0.5, 1, 3 or 5 parts by weight, relative to 1 part by weight of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof.
The incorporation ratio of polyethylene glycol monostearate in the aqueous liquid preparation of the present invention is within a range of the minimum content of about 0.2 part by weight to the maximum content of about 0.5 or 1 part by weight, relative to 1 part by weight of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof.
The preservative used in the present invention includes, for example, quaternary ammonium salts (e.g. benzalkonium chloride, benzethonium chloride, etc.), chlorhexidine gluconate, and the like, among which benzalkonium chloride is especially preferable.
Further, so long as the purpose of the present invention is achieved, conventional various additives such as isotonics, buffers, thickeners, stabilizers, chelating agents, pH controlling agents, perfumes and the like may be appropriately added to the aqueous liquid preparation of the present invention. The isotonics include sodium chloride, potassium chloride, glycerine, mannitol, sorbitol, boric acid, glucose, propylene glycol and the like. The buffers include, for example, phosphate buffer, borate buffer, citrate buffer, tartarate buffer, acetate buffer, boric acid, borax, amino acids, and the like. The thickeners include polyvinylpyrrolidone, carboxymethylcellulose, carboxypropylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, sodium polyacrylate, and the like. The stabilizers include sulfites such as sodium sulfite and the like. The chelating agents include sodium edetate, sodium citrate, condensed sodium phosphate and the like. The pH controlling agents include hydrochloric acid, sodium hydroxide, phosphoric acid, acetic acid and the like. The perfumes include 1-menthol, borneol, camphor, Eucalyptus oil, and the like.
With respect to the concentrations of the above various additives in the aqueous liquid preparation of the present invention,
the isotonic is incorporated into an osmotic pressure ratio of about 0.8 to 1.2, and the concentrations of the buffer and the thickener to be added are about 0.01 to 2 w/v and 0.1 to 10 w/v %, respectively.
The pH of the aqueous liquid preparation of the present invention is adjusted to about 6 to 9, preferably about 7 to 9, especially about 7.5 to 8.5.
So long as the purpose of the present invention is achieved, other same or different kind of active ingredients may be appropriately added.
The aqueous liquid preparation of the present invention can be prepared by per se known method or according to the method as described in the Japanese Pharmacopoeia, 14th Edition, General Rules for Preparations, Solutions or Ophthalmic solutions.
The aqueous liquid preparation of the present invention can be applied to warm-blooded animals such as human, rat, mouse, rabbit, cow, pig, dog, cat, and the like.
The aqueous liquid preparation of the present invention can be prepared easily by dissolving the above-mentioned components in, for example, distilled water or sterile purified water. For example, the aqueous liquid preparation in the form of an eye drop can be used for the treatment of inflammatory diseases in anterior or posterior segment of the eye such as blepharitis, conjunctivitis, scleritis, postoperative inflammation, and the like. The dose of the aqueous liquid preparation containing 0.1 w/v of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate hydrate is, for example, administered to an adult 3 to 6 times daily in an amount of 1 to 2 drops per one time. Depending on the degree of diseases, frequency of dosing is appropriately controlled.
The present invention is illustrated by way of the following Experimental Examples and Working Examples, but it is not restricted by these Examples.
Four eye drops of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate comprising the components as shown in Table 1 were prepared, filled respectively into a polypropylene container and subjected to stability test at 60° C.
The remaining rate (%) in the above Table 1 indicates values obtained by correcting moisture vaporization from the container. As is apparent from the Table 1, stability test was carried out under the conditions of pH 7.0 at 60° C. for 4 weeks, and sodium 2-amino-3-(4-bromobenzoyl)phenylacetate in each eye drop was stable in the order of tyloxapol-containing preparation>polyoxyl 40 stearate-containing preparation>polysorbate 80-containing preparation.
Further, with respect to eye drops containing tyloxapol (compositions A-02 and A-03), sodium 2-amino-3-(4-bromobenzoyl)phenylacetate in composition A-03 containing 0.02 w/v of tyloxapol is more stable than that in composition A-02 containing 0.15 w/v % of tyloxapol.
Five eye drops of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate comprising the components as shown in Table 2 were prepared, filled respectively into a polypropylene container and preserved at 60° C. for 4 weeks, and then the content of 2-amino-3-(4-bromobenzoyl)phenylacetic acid and the pH in each eye drop were measured.
Table 2 shows the remaining rate and the pH of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate after storage at 60° C. for 4 weeks, when the remaining rate of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate at the time of production of eye drops is set to 100%. The remaining rate is a value obtained by correcting moisture vaporization from the container. As is apparent from Table 2, the remaining rate of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate in the compositions A-04, A-05, A-06, A-07 and A-08 containing 0.02 w/v %, 0.03 w/v % and 0.05 w/v % of tyloxapol or 0.02 w/v % and 0.05 w/v % of polyoxyl 40 stearate is not less than 90 after storage at 60° C. for 4 weeks, which indicates that those compositions have sufficient stability for eye drops.
Preservative effect test of compositions A-04, A-05 and A-07 of Experimental Example 2 was carried out against Staphylococcus aureus (hereinafter referred to as S. aureus), Escherichia Coli (hereinafter referred to as E. coli), Pseudomonas aeruginosa (hereinafter referred to as P. aeruginosa), Candida albicans (hereinafter referred to as C. albicans) and Aspergillus niger (hereinafter referred to as A. niger).
The results are shown in Tables 3-1, 3-2 and 3-3.
S. aureus
E. coli
P. aeruginosa
C. albicans
A. niger
S. aureus
E. coli
P. aeruginosa
C. albicans
A. niger
S. aureus
E. coli
P. aeruginosa
C. albicans
A. niger
As is apparent from Tables 3-1, 3-2 and 3-3, the preservative effect of composition A-04 was found to be compatible with EP-criteria A in European Pharmacopoeia (EP), and those of compositions A-05 and A-07 were found to be compatible with EP-criteria B.
The EP-criteria A and EP-criteria B are given in the following.
EP-Criteria A:
Viable cell counts of bacteria (S. aureus, P. aeruginosa) 6 hours, 24 hours, and 28 days after inoculation decrease to not more than 1/100, not more than 1/1000, and undetectable, respectively.
Viable cell count of fungi (C. albicans, A. niger) 7 hours after inoculation decreases to not more than 1/100, and thereafter, the cell count levels off or decreases.
EP-Criteria B
Viable cell counts of bacteria (S. aureus, P. aeruginosa) 24 hours and 7 days after inoculation decrease to not more than 1/10 and not more than 1/1000, respectively, and thereafter, the cell count levels off or decreases.
Viable cell count of fungi (C. albicans, A. niger) 14 days after inoculation decreases to not more than 1/10, and thereafter, the cell count keeps the same level as that of 14 days after inoculation.
An eye drop is prepared using the above components in a conventional manner.
An eye drop is prepared using the above components in a conventional manner.
An eye drop is prepared using the above components in a conventional manner.
The aqueous liquid preparation of the present invention in the form of eye drops is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Such preparation is also useful for the treatment of nasal drop for treatment of, for example, allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.)
The present application is based on application No. 12427/2003 filed in Japan, and includes the entire contents thereof. By reference, the references including patents and patent applications cited herein are incorporated in the present application at the same level as when the entire contents thereof are disclosed. Furthermore, since it is obvious that the present invention can be carried out beyond the description of the above explanation and Working Examples, in light of the foregoing description, various other modifications and changes can be made to the present invention, and thus these modifications and changes should be considered to be within the scope of the claims appended hereto.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2003-012427 | Jan 2003 | JP | national |
| Number | Name | Date | Kind |
|---|---|---|---|
| 2880130 | Johnson | Mar 1959 | A |
| 2880138 | Johnson | Mar 1959 | A |
| 4045576 | Welstead, Jr. et al. | Aug 1977 | A |
| 4683242 | Poser | Jul 1987 | A |
| 4910225 | Ogawa et al. | Mar 1990 | A |
| 5110493 | Cherng-Chyi et al. | May 1992 | A |
| 5475034 | Yanni et al. | Dec 1995 | A |
| 5540930 | Guy et al. | Jul 1996 | A |
| 5558876 | Desai et al. | Sep 1996 | A |
| 5597560 | Bergamini et al. | Jan 1997 | A |
| 5603929 | Desai et al. | Feb 1997 | A |
| 5653972 | Desai et al. | Aug 1997 | A |
| 5942508 | Sawa | Aug 1999 | A |
| 5998465 | Hellberg et al. | Dec 1999 | A |
| 6071904 | Ali et al. | Jun 2000 | A |
| 6107343 | Sallmann et al. | Aug 2000 | A |
| 6162393 | De Bruiju et al. | Dec 2000 | A |
| 6274592 | Sawa | Aug 2001 | B1 |
| 6274609 | Yasueda et al. | Aug 2001 | B1 |
| 6319513 | Dobrozsi | Nov 2001 | B1 |
| 6369112 | Xia | Apr 2002 | B1 |
| 6383471 | Chen et al. | May 2002 | B1 |
| 6395746 | Cagle et al. | May 2002 | B1 |
| 8129431 | Sawa et al. | Mar 2012 | B2 |
| 20010056098 | Sawa | Dec 2001 | A1 |
| 20070082857 | Sawa | Apr 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 2204288 | Mar 1989 | AU |
| 707 119 | Sep 1995 | AU |
| 2 013 188 | Sep 1990 | CA |
| 2 383 971 | Mar 2001 | CA |
| 0 274 870 | Jul 1988 | EP |
| 0 306 984 | Mar 1989 | EP |
| 62-126124 | Jun 1987 | JP |
| 1-104023 | Apr 1989 | JP |
| 02083323 | Mar 1990 | JP |
| 2-124819 | May 1990 | JP |
| 5-223052 | Aug 1993 | JP |
| 9-503791 | Apr 1997 | JP |
| 11-228404 | Aug 1999 | JP |
| 2002-308764 | Oct 2002 | JP |
| 9405298 | Mar 1994 | WO |
| 9415597 | Jul 1994 | WO |
| 9614829 | May 1996 | WO |
| 0059475 | Oct 2000 | WO |
| 0115677 | Mar 2001 | WO |
| 0213804 | Feb 2002 | WO |
| Entry |
|---|
| Y. Hara, “Evaluation of New Drugs by Clinicians”, Clinics & Drug Therapy, vol. 19, No. 10, Oct. 2000, pp. 1-2. |
| G. Smolin, M.D., “New Drugs in Ophthalmology”, International Ophthalmology Clinics, vol. 36, No. 2, 1996, pp. 1-9. |
| ISTA News Release, XIBROM™, Bromfenac Ophthalmic Solution, 2007, p. 1. |
| S. Prince et al., “Analysis of Benzalkonium Chloride and its Homologs: HPLC Versus HPCE1”, Journal of Pharmaceutical and Biomedical Analysis, vol. 19, pp. 877-882, 1999. |
| M. Doughty, “Therapeutics: Medicines Update p18 Side-Effects of Anti-Epilepsy Drugs”, Optician, vol. 223, No. 5853, May 31, 2002, pp. 16-22. |
| I. Reddy, Ph.D., “Ocular Therapeutics and Drug Delivery”, Technomics Publishing Co., Basel, pp. 42-43, 390, 1996. |
| H. Schott, “Comparing the Surface Chemical Properties and the Effect of Salts on the Cloud Point of a Conventional Nonionic Surfactant, Octoxynol 9 (Triton X-100), and of its Oligomer, Tyloxapol (Triton WR-1339)”, Journal of Colloid and Interface Science, vol. 205, pp. 496-502, 1998. |
| O. Regev, “Aggregation Behavior of Tyloxapol, a Nonionic Surfactant Oligomer, in Aqueous Solution”, Journal of Colloid and Interface Science, vol. 210, pp. 8-17, 1999. |
| PDR 50th Edition 1996, Physicans' Desk Reference, p. 469. |
| PDR 54th Edition 2000, Physicans' Desk Reference, pp. 486-487, 491-492. |
| V. A. Ostrovskii et al., “Acid-Base Properties of 5-Substituted Tetrazoles”, Khimiya Get. Soc., pp. 412-416, 1981. |
| LOTEMAX™ product brochure, Loteprednol Etabonate Ophthalmic Suspension, 0.5%, pp. 1-16, Mar. 6, 1998. |
| Webester's New World Dictionary of the American Language, Second College Edition, “monohydrate”, Simon & Schuster, NY, p. 920, 1982. |
| Pharmacopeia, R. S. Cook et al., “Edetic Acid”, pp. 177-179, JT Steward, “Sodium Metabisulfide”, pp. 451-453, 2000. |
| Yakuji Nippo Limited, “Recent New Drugs 2001”, Japanese Pharmacopoeia 2001 Edition, pp. 27-29, May 2001 (English translation). |
| Sigma-Aldrich catalog, Biochemicals and Reagents for Life Science Research, p. 175, 2000. |
| G. Patani et al., “Bioisosterism: A Rational Approach in Drug Design”, Chemical Reviews, vol. 96, No. 8, pp. 3147-3176, 1996. |
| P. Deluca et al., “Interaction of Preservatives with Macromolecules IV, Binding of Quaternary Ammonium Compounds by Nonionic Agents”, Journal of the American Pharmaceutical Association, vol. 49, No. 7, pp. 430-437, Jul. 1960. |
| D. Guttman et al., “Solubilization of Anti-Inflammatory Steroids by Aqueous Solutions of Triton WR-1339”, Journal of Pharmaceutical Sciences, vol. 50, No. 4, pp. 305-307, Apr. 1961. |
| Fan et al., “Determination of Benzalkonium Chloride in Ophthalmic Solutions Containing Tyloxapol by Solid-Phase Extraction and Reversed-Phase High-Performance Liquid Chromatography”, Journal of Pharmaceutical Sciences, vol. 82, No. 11, pp. 1172-1174, Nov. 1993. |
| FDA Website search of Orange Book (Patent and Exclusivity Search Results): Approved Drug Products with Therapeutic Equivalence Evaluations; Search Results for N203168, 2014. |
| FDA website search of Orange Book (Detail Record Search): Approved Drug Products with Therapeutic Equivalence Evaluations, Search Results for N203168, 2014. |
| Remington: The Science and Practice of Pharmacy, 20th Edition, “Boric Acid”, Lippincoh, Williams, Baltimore MD, p. 1041, 2000. |
| PDR 52nd Edition 1998, Physicans' Desk Reference, “Duract”, Method Economics Co., Montrale, NJ, pp. 3035-3037. |
| ALREX™ product package, Loteprednol Etabonate, Ophthalmic Suspension, 0.2%, pp. 1-13, 1998. |
| XIBROM™ product package, Bromfenac Ophthalmic Solution, 0.09%, pp. 3-6, 2000. |
| BROMDAY product package, Bromfenac Ophthalmic Solution, 0.09%, pp. 4-8, 1997. |
| PROLENSA™ product package, Bromfenac Ophthalmic Solution, 0.07%, pp. 4-9, 2013. |
| PDR 54 Edition 2000, Physicans' Desk Reference, pp. 489-491, TOBRADEX®, Tobramycin and Dexamethasone Ophthalmic Suspension and Ointment. |
| FDA website description of VOLTAREN, Diclofenac Sodium, Ophthalmic Solution, 0.1%, pp. 1-2, 1991. |
| The United States Pharmacopeia, The National Formulary, USP 24, NF 19, pp. 1809-1813, 1864-1866, 2000. |
| Dorset & Baber, Webster's New Twentieth Century Dictionary, Second Edition, “Ophthalmic” and “Ophthalmitic” p. 1254, 1979. |
| BRONUCK® news release, Bromfenac Sodium Hydrate Ophthalmic Solution, p. 1, 2005. |
| Petition for Inter Partes Review of U.S. Pat. No. 8,669,290 to Sawa et al., Metrics, Inc. v. Senju Pharmaceutical Co., Ltd, pp. 1-71. |
| Petition for Inter Partes Review of U.S. Pat. No. 8,129,431 to Sawa et al., Metrics, Inc. v. Senju Pharmaceutical Co., Ltd, pp. 1-71. |
| New Drugs in Japan, 2001, 2001 Edition, Published by Yakuji Nippo Ltd., May 11, 2001, pp. 27-29, and its English translation of the material portions. |
| ISTA Pharmaceuticals, “New Drug Applications: Xibrom”, http://www.drugs.com/nda/xibrom—040525.htmt, accessed online Sep. 19, 2007. |
| Nolan et al., “The Topical Anti-Inflammatory and Analgesic Properties of Bromfenic in Rodents”, Agents and Actions, vol. 25, No. 1-2, pp. 77-85, Aug. 1988. |
| Corrected partial English translation of New Drugs in Japan, 2001, 2001 Edition, Published by Yakuji Nippo Ltd., May 11, 2001, pp. 27-29, previously submitted on Apr. 11, 2005. |
| Complete English translation of New Drugs in Japan, 2001, 2001 Edition, Published by Yakuji Nippo Ltd., May 11, 2001, pp. 27-29. |
| Notice of Opposition dated Feb. 19, 2009 issued by EPO in connection with the corresponding European patent application and Opposition. |
| http://medical-dictionary.thefreedictionary.com/prophylactic accessed Dec. 15, 2009. |
| ISTA News Release, XIBROM™, Bromfenic Ophthalmic Solution, 2007, p. 1. |
| T. Fan et al., “Determination of Benzalkonium Chloride in Ophthalmic Solutions Containing Tyloxapol by Solid-Phase Extraction and Reversed-Phase High-Performance Liquid Chromatography”, Journal of Pharmaceutical Sciences, vol. 82, No. 11, pp. 1172-1174, Nov. 1993. |
| FDA web site description of VOLTAREN, Diclofenac Sodium, Ophthalmic Solution, 0.1%, pp. 1-2, 1991. |
| Number | Date | Country | |
|---|---|---|---|
| 20150025149 A1 | Jan 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14261720 | Apr 2014 | US |
| Child | 14502014 | US | |
| Parent | 14165976 | Jan 2014 | US |
| Child | 14261720 | US | |
| Parent | 13687242 | Nov 2012 | US |
| Child | 14165976 | US | |
| Parent | 13353653 | Jan 2012 | US |
| Child | 13687242 | US | |
| Parent | 10525006 | US | |
| Child | 13353653 | US |
